Last updated on October 2018

An Open-Label Crenezumab Study in Patients With Alzheimer's Disease

Brief description of study

In the BN40031 OLE study, a dose of crenezumab of 60 mg/kg IV Q4W will be offered to all patients who complete Study BN29552 or BN29553 and who meet eligibility criteria in order to evaluate safety in patients on long-term crenezumab treatment and to investigate the effect of crenezumab on the underlying disease process and disease course as an exploratory efficacy objective.

Clinical Study Identifier: NCT03491150

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: BN40031 ...

Kawartha Centre - Redefining Healthy Aging
Peterborough, ON Canada
  Connect »